Evidence map›Paper›PMID 35064831›Full record

ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2022

Simultaneous mass spectrometry analysis of cisplatin with oligonucleotide-peptide mixtures: implications for the mechanism of action.

Farangis Mansouri, Luc Patiny, Daniel Ortiz, Laure Menin, Curtis A Davey, Fakhrossadat Mohammadi, Paul J Dyson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Farangis MansouriInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology Lausanne (EPFL), 1015, Lausanne, Switzerland.
Luc PatinyInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology Lausanne (EPFL), 1015, Lausanne, Switzerland.
Daniel OrtizInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology Lausanne (EPFL), 1015, Lausanne, Switzerland.
Laure MeninInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology Lausanne (EPFL), 1015, Lausanne, Switzerland.
Curtis A DaveySchool of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, 637551, Singapore.
Fakhrossadat MohammadiDepartment of Chemistry Institute for Advanced Studies in Basic Sciences (IASBS), 444 Prof. Sobouti Blvd., Gava Zang, 45137-66731, Zanjan, Iran. fmohammadi@iasbs.ac.ir.
Paul J DysonInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology Lausanne (EPFL), 1015, Lausanne, Switzerland. paul.dyson@epfl.ch.
École Polytechnique Fédérale de Lausanne · CHInstitute for Advanced Studies in Basic Sciences · IRNanyang Technological University · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although genomic DNA is the primary target of anticancer platinum-based drugs, interactions with proteins also play a significant role in their overall activity. In this study, competitive binding of cisplatin with an oligonucleotide and two peptides corresponding to segments of H2A and H2B histone proteins was investigated by mass spectrometry. Following the determination of the cisplatin binding sites on the oligonucleotide and peptides by tandem mass spectrometry, competitive binding was studied and transfer of platinum fragments from the platinated peptides to the oligonucleotide explored. In conjunction with previous studies on the nucleosome, the results suggest that all four of the abundant histone proteins serve as a platinum drug reservoir in the cell nucleus, providing an adduct pool that can be ultimately transferred to the DNA.

Indexed as

CisplatinHistonesDNAMass SpectrometryOligonucleotidesPeptidesPlatinumCisplatinDNAHistonesOligonucleotidesPeptidesPlatinumCisplatinDrug targetsHistone core particleMass spectrometry

Identifiers

PMID35064831
PMCPMC8907109
OpenAlexW4207074895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.